Skip to content

Earnings call

Jagsonpal Pharmaceuticals Q4 FY25 earnings call: Jagsonpal expects to achieve 15% plus revenue growth in the current year, with higher growth in operating profits and improved margins

By . Assembled by software from the company's transcript. Not reviewed by a person.

Transcript filed .

Jagsonpal expects to achieve 15% plus revenue growth in the current year, with higher growth in operating profits and improved margins. Counterfeit product availability in Indomethacin in FY '24, coupled with competitive intensity in the Dydrogesterone franchise, pulled down Jagsonpal's performance that year. Jagsonpal's therapeutic presence was almost 60% in gynae and about 30% in ortho till last year; gynae is now about 50%, with the other three therapeutic segments contributing about 15% each. The company extracted almost INR24 crores from working capital in the last 3 years and Manish Gupta did not foresee much further extraction.

The numbers management gave

Results

  • Counterfeit product availability in Indomethacin in FY '24, coupled with competitive intensity in the Dydrogesterone franchise, pulled down Jagsonpal's performance that year.
    Show source
    Coupled with the counterfeit product availability in Indomethacin the same year, it pulled down our performance for that year.
  • Jagsonpal's operating margins were in excess of 21%, working capital was 13 days or 3.5% of sales, and its cash balance was in excess of INR145 crores.
    Show source
    Today, JPL has among the best operating matrices amongst peers of its size, with operating margins in excess of 21%, working capital at 13 days or 3.5% of sales, and cash balance in excess of INR145 crores.
  • Jagsonpal's sales grew at 23% in the period, while operating EBITDA rose by 131% with a margin expansion of 1000 basis points.
    Show source
    Sales have grown at 23% in the period, while the operating EBITDA has risen by 131%, with a margin expansion of 1000 basis points.
  • Jagsonpal's PAT nearly doubled, with PAT margins expanding by 550 basis points.
    Show source
    Our PAT has nearly doubled, with PAT margins expansion by 550 basis points.
  • Jagsonpal's cash and cash equivalent surged 91%.
    Show source
    Cash and cash equivalent has surged 91%, underlying a robust financial foundation.
  • Jagsonpal generated over INR161 crores of free cash in the last three years, more than its operating EBITDA combined for that period, with almost INR24 crores coming from working capital reduction.
    Show source
    Overall, we have generated over INR161 crores of free cash in the last three years, which is more than our operating EBITDA combined for this period, as almost INR24 crores came out of working capital reduction.
Show 22 more statements

Results

  • Jagsonpal closed the quarter with revenue of 586 million against 435 million in last year's quarter, a growth of 34.7% and an absolute increase of 151 million.
    Show source
    And coming to the financial results, we closed our quarter with a revenue of 586 million against last year's quarter of 435 million, a growth of 34.7% and in absolute numbers it is 151 million gross.
  • Jagsonpal's operational EBITDA was 97 million against 49 million last year, a growth of 97%.
    Show source
    Talking about the operational EBITDA, it's 97 million against last year of 49 million, a growth of 97%.
  • Jagsonpal's operational EBITDA margin was 15.6% against 11.3% last year, a growth of 530 basis point.
    Show source
    In terms of margin, it is 15.6% against last year of 11.3%, a growth of 530 basis point.
  • Jagsonpal closed the quarter with PAT of 66 million against 35 million last year, a growth of 88.5%.
    Show source
    Talking about the PAT, we closed the quarter with a PAT of 66 million against 35 million last year, which is a growth of 88.5%.
  • Jagsonpal's PAT margin was 11.2% against 8.2% last year.
    Show source
    And in terms of the margin, PAT margin, it's 11.2% against last year of 8.2%.
  • Jagsonpal closed the year with revenue of 2,687 million against 2,087 last year, a growth of 28.8%.
    Show source
    Talking about the full year financial result, we closed the year with a revenue of 2,687 million against last year of 2,087, which is a growth of 28.8%.
  • Jagsonpal's official EBITDA was 579 million against 364 million last year, an increase of 59%.
    Show source
    And the official EBITDA was 579 million against last year of 364 million, an increase of 59%.
  • Jagsonpal closed the year with PAT of 554 million against 225 million last year.
    Show source
    And if I talk about the Page 4 of 15 Jagsonpal Pharmaceuticals Limited May 07, 2025 PAT, we closed the year with a PAT of 554 million against the last year of 225 million.
  • Jagsonpal's margins were 20.6% against 10.8% last year, a growth of 320 basis point.
    Show source
    And the margins are 20.6% and last year it was 10.8%, a growth of 320 basis point.
  • Jagsonpal's operating PAT after adjusting for the exceptional item was 375 million.
    Show source
    And the operating PAT after adjusting the exceptional item is, 375 million.
  • Jagsonpal's exceptional item related to the sale of the Faridabad facility and certain expenses incurred for the Yash Pharma acquisition; their combined impact was 197 billion as an income.
    Show source
    So the combined impact of the exceptional item was 197 billion as an income.
  • Jagsonpal closed the year with a cash balance of 145 crores.
    Show source
    And we closed the year with a cash balance of 145 crores.
  • Jagsonpal's Dydrogesterone franchise, formerly its largest at close to INR40 crores in internal revenue, dropped by almost 75% amid competitive intensity and limited pull from doctors; the business is now stable at less than INR10 crores or about INR1 crores a month.
    Show source
    Our business is now stable, but at a much lower level and less than INR10 crores or about INR1 crores a month.
  • Jagsonpal's growth during the year was 28%, of which 8% was organic and the rest inorganic; organic growth rose from 1% in H1 to 15% in H2 as strategies adopted from the second half of FY '24 began reflecting in faster growth, while H1 growth was lower because the Divatrone or Dydrogesterone franchise had fallen to a new level of business.
    Show source
    However, what is very important to note is this growth was 1% in H1, which has increased to 15% in H2.
  • Jagsonpal's volumes in the last 12 months would have been flat because of the drop in Dydrogesterone; volume increases in other products would have been compensated by the loss in Dydrogesterone volume.
    Show source
    Our volumes in last 12 months would have been flat and that is because of the drop in Dydrogesterone, I would say.
  • The company reduced its marketplace receivables through tighter controls, and its receivables were not more than 15 days of sales.
    Show source
    So our practices in the marketplace are aligned with the best in the industry and therefore our receivables in the marketplace are not more than 15 days of sales.
  • Medical representative productivity was INR2 to INR2.1 lakhs PCPM.
    Show source
    MR productivity, as we speak, is in the region of INR2 to INR2.1 lakhs PCPM or per capita per month.
  • Jagsonpal's organic growth fell short of its objectives.
    Show source
    Overall, I believe, there has been one area where we have fallen short of our objectives, which is organic growth.
  • Jagsonpal's majority growth would have come from price increases and/or new product introductions.
    Show source
    Largely, our majority growth would have come from price increases and/or new product introductions.

Money and capital

  • Jagsonpal concluded an investment of close to INR93 crores in an acquisition, alongside higher dividend payouts in the last two years.
    Show source
    This is after concluding an investment of close to INR93 crores in an acquisition, as also higher dividend payouts in the last two years.
  • Jagsonpal divested its Faridabad facility in Q3 for INR41 crores, enhancing growth capital and operational flexibility.
    Show source
    Further, we divested our Faridabad facility in Q3 for INR41 crores, thereby enhancing growth capital and operational flexibility.
  • The company extracted almost INR24 crores from working capital in the last 3 years and Manish Gupta did not foresee much further extraction.
    Show source
    In last 3 years, we have extracted almost INR24 crores from our working capital.

What it expects ahead

What management expects

  • Jagsonpal expects to achieve 15% plus revenue growth in the current year, with higher growth in operating profits and improved margins.
    Show source
    Amid evolving market dynamics and global trends, we expect to achieve 15% plus revenue growth in the current year, with a higher growth in our operating profits with improved margins.
  • Jagsonpal maintains its earlier guidance of 12%-14% revenue growth beyond FY26, with a potential 100-150 bps margin improvement year-on-year.
    Show source
    Beyond FY26, we continue to maintain our earlier guidance of revenue growth of 12%-14%, with a potential 100-150 bps margin improvement year-on-year.
  • Jagsonpal is guiding towards 15% growth in the current year.
    Show source
    So clearly going forward, that's why we are guiding towards the 15% growth in the current year as well.
  • The company aspired to increase medical representative productivity from about INR2 to INR2.1 lakh PCPM to between INR3 to INR3.5 lakhs PCPM over the next 3 to 4 years.
    Show source
    But our aspiration will be to take this which is currently about INR2 to INR2.1 lakh PCPM to between INR3 to INR3.5 lakhs PCPM over next 3 to 4 years.
  • Jagsonpal believes it will be back on track for its Dydrogesterone molecule from this year, but it will no longer be as relevant as it was in the past.
    Show source
    We believe we'll be back on road track as far as this molecule is concerned from this year, but it will no longer be as relevant as it was in the past.
  • The company expected to use cash only for acquisitions, which could be for brand acquisition and/or business acquisition; if it did not find any good targets in the next couple of years, the cash belonged to shareholders.
    Show source
    Investment or real use of cash is going to be only for acquisitions, which could be for brand acquisition and or business acquisition.

What it is building and selling

Projects and capacity

  • The company had no capex plan; its only investment was in computer infrastructure, including laptops in offices and in some select field force locations.
    Show source
    We do not have really any capex plan.

Segments

  • Indoca p became Jagsonpal's first INR50 crores brand in December.
    Show source
    Page 3 of 15 Jagsonpal Pharmaceuticals Limited May 07, 2025 In December, Jagsonpal also achieved a key milestone as Indoca p became our first INR50 crores brand.
  • Jagsonpal's therapeutic presence was almost 60% in gynae and about 30% in ortho till last year; gynae is now about 50%, with the other three therapeutic segments contributing about 15% each.
    Show source
    So we are 50% in gynae with the rest of the other three therapeutic segments contributing about 15% each.

Everything else said on the call

Group structure

  • Jagsonpal signed a business transfer agreement on May 16, 2024 to acquire the India and Bhutan business of Yash Pharma.
    Show source
    On May 16, 2024, Jagsonpal signed a business transfer agreement to acquire the India and Bhutan business of Yash Pharma.
  • Jagsonpal's acquisition of Yash Pharma's India and Bhutan business expanded therapeutic coverage into Derma and Pedia and strengthened reach in the western and eastern parts of the country, while expanding doctor reach by 50%.
    Show source
    It also strengthened our reach in the western and eastern parts of the country, as also expanded the doctor reach by 50%.

People and governance

  • Sachin Jain joined Jagsonpal as CFO in February 2025.
    Show source
    At the outset, I'm pleased to introduce Mr. Sachin Jain, our new CFO, who has joined us in February 2025.
  • Sachin Jain is a Chartered Accountant and an MBA in Finance with over 23 years of experience across multiple sectors.
    Show source
    Sachin is a Chartered Accountant and an MBA in Finance, and he brings in over 23 years of experience across multiple sectors.
  • The company had about 1,000 medical representatives in its field force, give or take 10 or 20, and did not change field force strength except for the acquisition that brought in about 250 representatives through the Yash Pharma acquisition.
    Show source
    So obviously, new field force came in with about 250 reps through Yash Pharma acquisition.

What the company said on its earnings call, taken from its own transcript. Not advice.

Questions and answers

  1. Question

    Ankur Bhadekar: Yes. So my second question is that you mentioned that you will be launching four to six new products annually. So what would be the nature of these upcoming launches? And will there be primarily extensions of existing brands or entirely new molecules? These were the two questions.

    Answer, manish gupta

    Manish Gupta: Yes, thank you, Ankur. So let me first respond to your first question, which was pertaining to Divatrone or Dydrogesterone. Clearly, that market has undergone significant transition in the last three years. While the molecule has grown, so has the competitive intensity. And we had at one point of time close to 100 competitors in that market. The growth of that molecule thereby stopped. So, of course, it grew to about INR1,000 crores molecule as per IQVIA.

    Answer, manish gupta

    But given the competitive intensity, it became a push molecule rather than a pull molecule at the doctor level. From our perspective, at one point of time, this Dydrogesterone franchise was the largest and close to INR40 crores in terms of internal revenue. Both the competitive intensity and wherein there was a lot of push and as I said, there was very little pull element, we took a backseat as far as this molecule is concerned and it has dropped by almost 75% for us. Our business is now stable, but at a much lower level and less than INR10 crores or about INR1 crores a month. We believe we'll be back on road track as far as this molecule is concerned from this year, but it will no longer be as relevant as it was in the past. That's point number one, as far as Divatrone is concerned. Page 5 of 15 Jagsonpal Pharmaceuticals Limited May 07, 2025 Your other question was on new product strategy.

    Answer, manish gupta

    Clearly, while I cannot disclose too much about it, JPL strength is doing well in niche smaller molecules. Div atrone or Dydrogesterone was one exception in that. So we will be sticking back to our basics, which is picking up niche areas and taking a more meaningful share in those molecules. About half of our new launches would be brand extensions and half would be totally new product concepts. At this point of time, that's what I can reveal as far as our new product strategy is concerned. So you would have noticed that in the last 12 months, more or less, the strategy has played out. We became the first company to launch a post -menopausal product in the country.

    Answer, manish gupta

    We also launched Queezy ER, which was ER version for morning sickness. In fact, the product just got a patent for the CMO that supplies us the product. So these are really the strategies that we have used. And at the same time, the expansion strategy, which I was just mentioning, our Indocap P, which is a combination of Indomethacin and Paracetamol is a brand expansion strategy that I just highlighted. So that will continue to be broad strategy as far as the company is concerned. Does that answer, Ankur?

  2. Question

    Ankur Bhadekar: Yes, sir. And one more question about the therapeutic revenue mix between gynae, ortho, derma and pediatrics in your portfolio, like what does the current mix look like for FY '25 and how do you see it evolving with the addition of Yash Pharma? So do you expect the contribution from derma and pediatrics to increase given that most of Yash Pharma's products are mass market, if I'm not mistaken?

    Answer, manish gupta

    Manish Gupta: That's correct. So the product mix has already changed. Till last year, our therapeutic presence was almost 60% in gynae and about 30% in ortho. So that was our product mix. As we speak, Gynae now is about 50%. We still continue to be a gynae-dominated company. So we are 50% in gynae with the rest of the other three therapeutic segments contributing about 15% each.

  3. Question

    Ankur Bhadekar: Okay. And lastly, historically, if we check, Q4 has always been weaker as compared to the other quarters. So is there a specific reason for this? Is it due to any seasonality in the nature of the business?

    Answer, manish gupta

    Manish Gupta: Yes and no. There's very little seasonality, but the stockist purchases come down in Q4. So Q4 is always weaker for us as also for others who are in domestic markets. Now why it does not reflect so strongly in other companies is because they are both in India and outside India. And generally, in businesses outside India, the Q4 is the strongest. So therefore, it gets balanced in other companies. JPL is purely a domestic pharma -focused company. Therefore, our Q4 continues to be always weaker than the rest of the three quarters.

    Answer, manish gupta

    It's a bit of seasonality, but more importantly, I think the purchasing behaviors of stockists who do not tend to pick up much quantity in March.

  4. Question

    And also for organic, can you break it down into volume, price and new product for FY '25?

    Answer, manish gupta

    Manish Gupta: Let me respond to the extent I can. So clearly, the first part of your question, breaking into organic and inorganic, I have a very clear answer. 8% of our growth is organic growth and the rest is inorganic. So while we have reflected a 28% growth during the year, 8% of that has come from organic. However, what is very important to note is this growth was 1% in H1, which has increased to 15% in H2. Clearly, the change of strategies that we had adopted from second half of previous year in FY '24 has started reflecting in faster growth. H1 was lower growth because that's where we bore the brunt of Divatrone or Dydrogesterone franchisee coming down to a new level of business.

    Answer, manish gupta

    So clearly going forward, that's why we are guiding towards the 15% growth in the current year as well. Now, coming to your second part of question, it is a very difficult question simply because the product mix keeps changing and it has changed dramatically, especially because of Yash Pharma acquisition. Largely, our majority growth would have come from price increases and/or new product introductions. Our volumes in last 12 months would have been flat and that is because of the drop in Dydrogesterone, I would say. So whatever volume increases would have occurred in other products would have been compensated by the loss in volume of Dydrogesterone. Aditya Chheda: Got it. And the outlook that is shared for growth is all a function of organic outlook that you are looking forward to, right?

    Answer, manish gupta

    Manish Gupta: That's true. Excepting for a small, because Yash Pharma business was there for 10 months last year versus 12 months, which it will be for this year, everything else is organic growth. We cannot -- we can never kind of estimate what will happen inorganically. So we do not build it in our forecast or guidance.

  5. Question

    Aditya Chheda: Got it. And the last question is on the slide on networking capital where it has come down to almost 3.5% of sales. Can you talk more about the initiatives that were taken forward and how do you see the outlook for the networking capital days or as a percentage of sales going forward? Thanks. These are the questions. Thank you so much.

    Answer, manish gupta

    Manish Gupta: Very, very, valuable question because this is something that we pride ourselves in. All we manage our working capital very efficiently. So clearly it was a function of two things. We reduced our receivables in the market through tighter controls. We are now a very disciplined company. Every order is backed by check and we En-Cash checks well on time. So our practices in the marketplace are aligned with the best in the industry and therefore our receivables in the marketplace are not more than 15 days of sales.

    Answer, manish gupta

    That is one part of it. The second part of it came out of reduction in our inventories. From better forecasting, planning and management. That is again something which we have been able to bring down considerably in terms of days of sales. And so these are two areas wherein we could bring down our working Page 7 of 15 Jagsonpal Pharmaceuticals Limited May 07, 2025 capital significantly. However, on the other side, creditors have also come down. Okay.

    Answer, manish gupta

    So earlier we never paid our creditors or vendors on time. But for last 18 months, every vendor is paid on the due date, which is a principle that we have adopted in our company. And in spite of that, our working capital has come down. So great, I think, hygiene, the way we conduct business internally, as well as how we treat our vendors. That has, of course, facilitated some of our cost reductions, which is also reflected in improved gross margins in the business. So -- and if you were to ask us going forward, I think most of the low-hanging fruits around working capital are now there in place. Reducing it below 3% is going to be not really much different from where we are today.

    Answer, manish gupta

    So that phase is over. In last 3 years, we have extracted almost INR24 crores from our working capital. I don't foresee much extraction going forward.

  6. Question

    Subrata Sarkar: Yes. So I have one simple question, sir. Like, what is the, like, on-field manpower that we have added in the last 1 year? And what is the productivity of this MR basically? So if you can highlight, like last prior to 1 year, what was the average productivity? And right now, what is the average productivity? And what is our intention or target or let's say goal, like in terms of average productivity, where we want to reach? market conditions, industry average.

    Answer, manish gupta

    Manish Gupta: Yes. Thanks, Subrata. That's really a good question. So basically, our current medical rep strength would be about 1,000 in the field force, give or take 10 or 20 or numbers here and there. We have not really changed our field force strength, excepting for the acquisition that we did. So obviously, new field force came in with about 250 reps through Yash Pharma acquisition. MR productivity, as we speak, is in the region of INR2 to INR2.1 lakhs PCPM or per capita per month.

    Answer, manish gupta

    And the 8% growth that we are talking of actually has come from increased MR productivity. Is there a scope of doing this? Answer is yes. So I don't foresee us increasing our field force strength over the next 2 to 3 years. Clearly, there is the ability to increase this field force productivity by at least 50%. And that's what we are aspiring or working on. So does that answer your question?

  7. Question

    Subrata Sarkar: Yes, sir. But do we have any like, like I know generally industry average is a little bit higher. So, like where do we want to reach there as such? And do we have any target on that? Not maybe in specific numbers, but at least some ballpark.

    Answer, manish gupta

    Manish Gupta: So I must admit that our PCPM will always be a bit lower than the industry or big -- big leaders average. The reason is that we are in sub chronic segments and not in chronic segments. And most of our products are high intervention products in gynecology. So they support pregnancies. They're not general offtake products, as most or many companies have. So these are highly prescription driven products. So productivity is going to be little lower than where many good Page 8 of 15 Jagsonpal Pharmaceuticals Limited May 07, 2025 companies will be.

    Answer, manish gupta

    But our aspiration will be to take this which is currently about INR2 to INR2.1 lakh PCPM to between INR3 to INR3.5 lakhs PCPM over next 3 to 4 years.

  8. Question

    Subrata Sarkar: Okay. So now, another two question one is, can you like in your slide you have shared, but even still if you can explain like, why we called off the Resilient acquisition basically?

    Answer, manish gupta

    Manish Gupta: Yes, so there were certain conditions precedence to the transaction. Largely, these were related to certain challenges around the key trademarks. Fundamentally, when you buy a business in India, you're buying trademarks and the field force. And the valuable thing there is trademarks. A couple of trademarks had certain CPs because they had to get them corrected. That was something they were unable to do within the timelines, which we had forecasted. And that was the reason why both the companies mutually decided to terminate that contract.

  9. Question

    Subrata Sarkar: Okay. Last question, more of a from a strategic point of view, since the last like, around 50% of our business comes from a particular therapeutic segment. And like, as you told, we don't have much intention to increase our strength in next two years, isn't it? And we have cash in our books. So isn't it a better like from a strategic point of view, isn't it a better opportunity or option for us? Rather than acquiring a new company, if we go for a particular brand in our strength therapeutic area, if a few brands are available in gynecology area. And if we can add them like by one or two, and then like add up to use our sales force to ramp it up, isn't it a better opportunity

    Answer, manish gupta

    Manish Gupta: Absolutely right. You're bang on. Clearly, our first intent is to ideally acquire something which can which fits our strategy in the therapeutic areas that we are present. Having said that, the constraint there is, A, transactions are limited. And B, the asking prices are very, very high. I mean, recent brand acquisitions have been in the region of eight to 10 times scale. And sometimes it becomes very difficult to compete at those levels of valuation.

    Answer, manish gupta

    So strategically, you're absolutely right. Our preferred approach would be brand acquisitions over business acquisition, but at valuations which su its us.

    Answer, manish gupta

    Manish Gupta: Okay. And what is your next? If you can ask all your questions in one shot and then we can respond.

  10. Question

    Majid Ahamed: Okay. Sir my second question is, sir, going forward, what type of capex that you're looking to do with your cash? Like some sort of understanding that going forward, what is your capex plans going forward? Page 9 of 15 Jagsonpal Pharmaceuticals Limited May 07, 2025 Manish Gupta: So let me first take the first part of the question.

    Answer, manish gupta

    See, India is a complex market. And in a way, there are price points, different price points for every product based on customer or consumers. Okay. So every product, Indomethacin or Dydrogesterone or any other molecule, there will be products available at higher price, and there will be products available at lower price. And there will be, in fact, products available at virtually no price, which is generous. Okay. So it finally boils down to the quality of doctors and quality of patients you cater to.

    Answer, manish gupta

    Okay. So every company has its own strategy on where they target themselves. And that's how pricing decisions are taken. And you create your own niche in the doctor's chamber. Jagsonpal is focused on specialists. And therefore, we are comparatively mid to higher price brand in the doctor's chamber. And all our sales happen to prescriptions.

    Answer, manish gupta

    So when a doctor prescribes a brand, generally, especially in the areas we are in, they're less likely to be substituted. So it's a matter of strategy on where you want to price your product. And generally, you tend to have a consistent strategy. So you can't have one product high price and one product low price. Generally, that doesn't work. JPL, our prices will be generally on the higher bracket. Your second question was around capex.

    Answer, manish gupta

    If you notice, we follow an asset light model. We are purely in India. And therefore, all our products for India are using CMOs, which have plenty in this country. We do not have really any capex plan. Our only investment is in computer infrastructure, the laptops and all that we have in offices and in some select field force locations. Investment or real use of cash is going to be only for acquisitions, which could be for brand acquisition and or business acquisition. If we do not find any good targets in the next couple of years, of course, this cash belongs to the shareholders.

    Answer, manish gupta

    And we would be rather returning this cash in an appropriate form to the shareholders rather than doing anything not in line with our strategy.

Show 5 more questions
  1. Question

    Amayra Shah: Yes. So I have two questions. So firstly in the present scenario, how is the company strategically positioning itself to maintain its market share? And second question is what like is there any steps being taken by the company to mitigate the current pricing pressures?

    Answer, manish gupta

    Manish Gupta: Current pricing pressures. We don't see any pricing challenges at all in India, because that pricing pressure that you're referring to a competitive intensity that you're referring to is more outside India, which are unbranded generic markets or generic-generic markets. India is a branded generic market. While there are different price points, companies have their own strategy in terms of their presence in doctor's chamber and they have the price point accordingly. So there are low price companies, there are mid price companies and there are high price companies. We fall somewhere in between the second and the third round in the sense between mid price to high price. So we, our prices generally tend to go up.

    Answer, manish gupta

    We don't reduce our prices. Having said that our value proposition to the doctor is around science. And that's an area we keep working on how do we keep adding to the science around both the molecule and also around the doctor practice because doctor needs to be updated on latest trends. That's a knowledge thing that we keep providing to doctors. And, of course, bringing in certain unique products which are useful for the patient and thereby the doctor practice. So that's fundamentally a business policy. That's the way we conduct business.

  2. Question

    Amayra Shah: Okay. Thank you.

    Answer, manish gupta

    Manish Gupta: So coming to your first question. Yes, Q4 is slightly milder and Q1 is to that extent slightly better. So that is certainly the case. Q2 and Q3 are best in terms of seasonality. So you'll see typically Q1, Q2, Q3 are better for the domestic pharma industry versus Q4. Q1 on account of, I mean, stock is not buying in March and they end up picking larger volumes in April. And Q2, Q3, because of seasonality of some products because those are the periods when people tend to become unwell more than regularly.

    Answer, manish gupta

    Q4 being the weakest. So that's the trend. Page 11 of 15 Jagsonpal Pharmaceuticals Limited May 07, 2025 And this is common for most companies. If you look at the historical Jagsonpal portfolio, given that we are more Gyne and a bit of Ortho, Gyne there is no seasonality, Ortho there is some seasonality, especially for winters. Yash Pharma is, of course, a very, the business that we acquired from Yash Pharma is of course a little different animal in that sense, because Yash Pharma is Derma and Pedia. Pedia has stronger demand in Q3 and Q4, while Derma has stronger demand in Q1 and Q2. So Derma is summer oriented, because that's when you have fungal infections and whatnot, when it is too hot.

    Answer, manish gupta

    And Pedia is winter oriented, because that's when again coughs cold and all the kids get sick. So now our business is a little more curious mix as compared to what it was prior to Yash Pharma acquisition. That is point one. Your second question pertaining to acquisition strategy, I don't have an answer per se. Yes, clearly it is expensive. So we keep trying to balance in terms of pricing. For Resilient transaction, while it would have been a good to have transaction, but it was not a need to have transaction.

    Answer, manish gupta

    So therefore, strategically, it had its importance. It came to us at a fair price, but you cannot compromise on brands, right? So if the brand is under certain dispute, which is unable to be resolved, there is no point of buying a business. So that's why we walked out of that or we kind of mutually terminated that transaction. So that's it, it doesn't really bother us. It was a small transaction. It would have been useful, certainly, but nothing that derails our strategy and our business.

  3. Question

    Majid Ahamed: Sir, my last question that is for doing modeling or understanding business even better, like what type of KPIs can we track going for the company?

    Answer, manish gupta

    Manish Gupta: Ours is a very simple business because we don't have too many moving parts in our business. So it's all about tracking growth. And I think there was one question, I think Jatin, you had asked and I missed out in that and that will partly answer your question also. So Jatin, you had asked whether we are satisfied with the growth objectives that we delivered in Q4 or even maybe full year. So as I mentioned in my opening remark, that is, there's only one area where I feel a bit disappointed in my last 3 year journey, which is organic growth. If you take our last three years of growth, it is only about seven to 8% year on year. Even this year, the organic growth was 8%.

    Answer, manish gupta

    That is something certainly below our expectation. Are we growing? Answer is yes. Are we growing as much as we would like to? The answer is no. Page 12 of 15 Jagsonpal Pharmaceuticals Limited May 07, 2025 And it's not for want of efforts, but it's something or the other keeps happening and that has kind of reduced our growth rates. We hope to be back on faster growth from this year onwards. So Majid, now partly responding to your question in that, for us, for you to model us out, it's all about growth.

    Answer, manish gupta

    Because rest is a flow through. We are very confident. A difference in our P&L would be whether we are able to grow 8%, 12% or 15%. That will dramatically or reasonably alter our profitability profile, because most of our costs are fixed costs. So other than costs, we are about a 65% margin gross-margin business. But between gross-margin to EBITDA, I would say 95% of our costs are fixed costs. So if we grow at 15%, if we are able to demonstrate that growth rate, certainly that's our aspirational target internally.

    Answer, manish gupta

    Gross-margins will improve by 100 bps every year. And with operating costs not growing in line with that top-line growth, our operating margins will keep expanding. So therefore, the easiest way to track our fundamental KPI that you should track is growth. Moment we are in double-digit, I think, or little more than double -digit, 12% to 15%, our operational profit will grow 25% plus, without any doubt.

  4. Question

    Majid Ahamed: The thing is that there is more fixed costs and whatever additional revenue coming in, that will directly flow into the bottom?

    Answer, manish gupta

    Manish Gupta: That's fine. Because other than these, really, none of our fixed costs increase.

  5. Question

    Praval Shah: Yes. Great share of results. Also, wonderful insights onto the working capital management. But an observation on that, so since we have more cash and that cash doesn't find its way in building more plants and machinery, just a question, if you can help us understand, will we be amping up our R&D investments in order to go after truly differentiated, maybe first-to-file products and build that muscle slowly? And maybe in therapies of our choice, in gynecology or maybe even in dermatology now, or are we steadfast in terms of acquiring other companies in an organic way or distributing the back to the shareholders? So, if you could just give a qualitative understanding of allocation

    Answer, manish gupta

    Manish Gupta: So, Praval, basically in India, there's nothing called first-to-file or anything, fundamentally. So, India is either a patent or a off-patent market, right? So, the moment the patent expires, then Page 13 of 15 Jagsonpal Pharmaceuticals Limited May 07, 2025 there'll be 10 and even 100 companies in market. And you'll soon see it happening when the GLP-1 brands come in. So, very little to differentiate or constraint supplies in India, because the moment patent is off, there is no other protection except in building your own brands. So, and also investing too much in R&D in India, because unless you develop absolutely new patentable products, otherwise, which is not something any company has been able to do for India or otherwise. So, there's not really much you can spend on R&D as far as India businesses are concerned.

    Answer, manish gupta

    You do spend on R&Ds in developing concepts, you do spend in terms of establishing efficacies and whatnot, but it is not really a new molecule development that you spend for India. So, having said that, therefore, come what may, a real capex, if any for us, can be only in acquisitions. For us, acquisition is a matter of both opportunity and strategy, but disciplined execution is very, very critical, because going wrong on price is the easiest you can do, especially when you're sitting on surplus cash. So, to that extent, I must admit that our board is extremely disciplined and focused. So, even if I try, there's no way my board will allow me to splurge money in stupid acquisitions or overpriced acquisitions. We are also very clear that if we do not find right targets, this money eventually belongs to shareholders. So, unless we can find something which adds value to our shareholders, it is better to return it rather than doing any acquisition for pride.

Questions about this call

When was the Jagsonpal Pharmaceuticals Q4 FY25 earnings call transcript filed?
Jagsonpal Pharmaceuticals filed the transcript with the exchange on 13 May 2025. This page is built from that transcript.
What does this page list?
42 statements from the transcript across 7 topics, 32 of them with a figure. Each statement is shown with the transcript sentence it came from.
Are the analysts' questions included?
Yes. 15 questions and management's answers are listed in the order they were asked, as the transcript prints them.
Who wrote this page?
DalalOS Data Desk. Assembled by software from the company's transcript. Not reviewed by a person. How it is made, and what it leaves out, is on the method page linked from the byline.
Research and analysis only, not investment advice. Every statement on this page is the company's own, taken from its transcript; DalalOS adds no view on it and is not a SEBI-registered investment adviser. Something wrong? Report an error.
Jagsonpal Pharmaceuticals Q4 FY25 concall: Jagsonpal expects to achieve 15% plus revenue growth in the current year, with higher growth in operating profits and improved margins · DalalOS